



08003025

Antisoma receives USD 25 million milestone payment from Novartis

London, UK, 29 May 2008 – Antisoma (LSE:ASM; USOTC:ATSMY) announces that it has received a milestone payment of USD 25 million from Novartis. This was triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer.

Enquiries:

Glyn Edwards, CEO

Daniel Elger, Director of Communications

Antisoma plc

+44 (0)7909 915 068

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich +44 (0)20 7466 5000
Buchanan Communications

Brian Korb
The Trout Group

+1 646 378 2923

SUPPL

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Background on Antisoma

Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma.

PROCESSED

JUN 09 2008
THOMSON REUTERS

JW 6/5

END

RECEIVED
21 09 JUN -4 A 1:2
THOMSON REUTERS